Teva Pharmaceutical Industries Limited (NYSE:TEVA) Position Boosted by Russell Investments Group Ltd.

Russell Investments Group Ltd. boosted its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 33.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 204,447 shares of the company's stock after acquiring an additional 51,601 shares during the quarter. Russell Investments Group Ltd.'s holdings in Teva Pharmaceutical Industries were worth $4,506,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of TEVA. Stifel Financial Corp boosted its stake in shares of Teva Pharmaceutical Industries by 54.0% in the third quarter. Stifel Financial Corp now owns 66,391 shares of the company's stock valued at $1,196,000 after purchasing an additional 23,283 shares during the period. Robeco Institutional Asset Management B.V. boosted its position in Teva Pharmaceutical Industries by 7.2% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company's stock valued at $10,983,000 after buying an additional 33,277 shares during the last quarter. Pinnbrook Capital Management LP purchased a new position in Teva Pharmaceutical Industries in the 4th quarter valued at about $4,966,000. Asset Management One Co. Ltd. grew its stake in shares of Teva Pharmaceutical Industries by 14.6% during the fourth quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company's stock valued at $10,414,000 after acquiring an additional 58,413 shares in the last quarter. Finally, CWA Asset Management Group LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth about $3,340,000. Institutional investors and hedge funds own 54.05% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Bank of America lowered their price objective on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research note on Thursday, March 6th. UBS Group dropped their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research note on Thursday, January 30th. Piper Sandler increased their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research note on Friday, January 17th. StockNews.com lowered shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a report on Monday, April 14th. Finally, Barclays cut their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, January 30th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $23.43.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE TEVA traded down $0.35 during midday trading on Monday, hitting $13.30. The company's stock had a trading volume of 12,058,632 shares, compared to its average volume of 9,911,347. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. Teva Pharmaceutical Industries Limited has a 1-year low of $12.47 and a 1-year high of $22.80. The firm's fifty day moving average price is $15.39 and its 200-day moving average price is $17.65. The firm has a market cap of $15.08 billion, a P/E ratio of -9.17, a P/E/G ratio of 1.44 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, sell-side analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.